Cyclophosphamide: Brands, Price & Uses in Bangladesh

Cyclophosphamide is an alkylating agent used, either alone or in combination with other antineoplastic agents, in the treatment of a variety of malignancies and severe autoimmune conditions.

FDA-approved / established uses

• Malignant lymphomas (Hodgkin and non-Hodgkin lymphoma)
• Multiple myeloma
• Leukemias, including chronic lymphocytic leukemia, chronic granulocytic leukemia, acute myelogenous and acute lymphoblastic leukemia
• Mycosis fungoides (advanced disease)
• Neuroblastoma (disseminated disease)
• Adenocarcinoma of the ovary
• Retinoblastoma
• Carcinoma of the breast
• Biopsy-proven minimal change nephrotic syndrome in children who have not responded adequately to corticosteroid therapy

Guideline-supported / specialist off-label uses

• Severe lupus nephritis and other severe manifestations of systemic lupus erythematosus (as part of specialist-directed immunosuppressive protocols)
• ANCA-associated vasculitis (e.g. granulomatosis with polyangiitis, microscopic polyangiitis), typically for remission induction
• Severe, refractory rheumatoid arthritis and other autoimmune/connective tissue diseases unresponsive to standard therapy
• Conditioning regimen prior to hematopoietic stem cell/bone marrow transplantation

Use for autoimmune indications and as part of multi-agent chemotherapy regimens should only be initiated and supervised by a specialist experienced in the use of cytotoxic/immunosuppressive therapy.

Dosing of Cyclophosphamide is highly individualized based on indication, treatment protocol, combination regimen, and patient hematologic/renal/hepatic status. Treatment must be prescribed and monitored by a physician experienced in cytotoxic chemotherapy or immunosuppressive therapy.

Adequate hydration (oral or IV fluids) and, for higher doses, prophylactic use of mesna are used to reduce the risk of hemorrhagic cystitis. Antiemetic prophylaxis is generally required. Complete blood counts must be monitored before and periodically during therapy, with dose modification for significant myelosuppression.

Renal impairment: Dose reduction is generally recommended in significant renal impairment because active/toxic metabolites may accumulate; adjust per protocol and specialist guidance.

Hepatic impairment: Use with caution and consider dose reduction in patients with significant hepatic impairment (e.g. elevated bilirubin), as hepatic activation of the prodrug may be affected.

Cyclophosphamide carries serious dose-related toxicities in addition to common adverse effects.

Serious/boxed-warning-level risks

• Myelosuppression: Neutropenia, thrombocytopenia, and anemia, increasing risk of serious infection and bleeding; requires regular blood count monitoring.
• Hemorrhagic cystitis: Caused by the toxic metabolite acrolein; presents as bladder irritation, hematuria, and dysuria. Risk is reduced with adequate hydration and, at higher doses, mesna prophylaxis.
• Cardiotoxicity: Particularly with high-dose regimens (e.g. transplant conditioning); can cause hemorrhagic myocarditis and heart failure.
• Secondary malignancy: Long-term use is associated with increased risk of bladder cancer, myelodysplastic syndrome, and acute leukemia.
• Infertility: Can cause amenorrhea, ovarian failure, azoospermia, and testicular atrophy, which may be irreversible.
• Pulmonary toxicity: Interstitial pneumonitis and pulmonary fibrosis have been reported, especially with prolonged therapy.
• Impaired wound healing and increased infection risk due to immunosuppression.

Common adverse effects

• Nausea and vomiting
• Alopecia (hair loss, usually reversible)
• Anorexia, mucositis/stomatitis
• Diarrhea
• Metallic taste, facial flushing during infusion
• Fatigue
• Syndrome of inappropriate antidiuretic hormone secretion (SIADH) at high doses